Pharming Group N.V. (PHAR) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to Farming Group NV third quarter 2025 results conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 and 1 on your telephone. you will then hear an automated message advising your hand is raised. To withdraw your question, please press star one and one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Fabrice Chiraki, Chief Executive Officer. Please go ahead. Thank you, operator. Good morning and good afternoon, everyone, and welcome to the Farming's Q3 2025 earning call. I'll be joined on this call today by Steve Torr, our Chief Commercial Officer, Anurag Rannan, our Chief Medical Officer, and Kenneth Leonard, our new Chief Financial Officer. On this call, we will be making forward-looking statements that are based upon our current insights and plans. As you know, these may well differ from future results. As you saw in our press release earlier today, we delivered another very strong quarter. Total revenues grew by 30% in the third quarter of 2025 versus the same quarter last year. And operating profits jumped to $15.8 million, nearly four times last year's results. Operating cash flow came at $32 million, turning our cash position almost back to where it was at the end of 2024, before the acquisition of Abreva. Our strong top-line growth was fueled by the continued significant growth of our two commercial assets, Ruconest and Joe & John. Ruconest grew 29% year-on-year, fueled by continued strength in new prescribers and in new patient enrollments, even...